Gaucher drug boost for Shire

PHARMACEUTICALS firm Shire is today expected to announce it has been granted treatment protocol by the Food and Drug Administration for its yet-to-be-approved drug for Gaucher Disease.<br /><br />The treatment protocol will allow Shire to make the product available to patients on a compassionate basis, before gaining commercial approval. <br /><br />The new drug, Velaglucerase, has been pushed forward after fears of a shortfall in treatment following a production shutdown at a plant run by rival pharmaceutical firm Genzyme.<br /><br />The market is worth $1.2bn (&pound;716m).